Our Division of Training, Workforce Development, and Diversity (TWD) supports programs at multiple career stages to foster the development of a strong and diverse biomedical research workforce. This post is the first in a series focused on data from NIGMS training programs and is similar to the ones we have done for our research project grant portfolio. Below, we examine trends in NIGMS applications and awards for the Individual Postdoctoral National Research Service Award (NRSA) (F32) and Pathway to Independence Award (K99) programs. NIGMS also supports institutional postdoctoral awards that include the Institutional Research and Academic Career Development Awards (IRACDA) (K12) and NRSA Institutional Postdoctoral Training Grants (T32) focused in clinical areas, and data on these programs were shared previously.
Continue reading “NIGMS Training Application and Funding Trends: Individual NRSA Postdoc and Pathway to Independence Awards”
One of the most common questions we receive about the Maximizing Investigators’ Research Award (MIRA) program is the likelihood of an application’s funding given a certain overall impact score.
Frequent readers of this blog may note that we typically provide statistics as they relate to our R01 portfolio, but we’ve yet to provide a similar “funding curve” for the MIRA program. One reason that MIRA applications haven’t been included in these analyses is that, unlike most R01 applications, MIRA R35 applications don’t receive a percentile score. The percentile score allows for normalization of overall impact scores across study sections to account for any differences in scoring behavior that are observed in review panels. See the Office of Extramural Research’s comprehensive blog post for more information about overall impact scores and percentiles.
Continue reading “Funding Trends: MIRA Applications and Overall Impact Scores”
Because many people in the research community are facing considerable challenges trying to juggle various responsibilities during the COVID-19 outbreak, NIGMS will accommodate late application submissions for due dates in May 2020 for all NIGMS-specific FOAs (see NOT-GM-20-029). For applications submitted through June 30, 2020, institutions do not need to request advance permission or provide a cover letter to justify a late submission to these FOAs. Applications with due dates prior to May 25 should use FORMS E and those with due dates on or after May 25 should use FORMS F, regardless of the date of submission.
Continue reading “Policy on Late Submissions of NIGMS Applications Due in May 2020”
Ninety percent of the applications to our Maximizing Investigators’ Research Award for Early Stage Investigators (known as the ESI MIRA program) that were submitted in October are about to undergo peer review. The remaining 10% were administratively withdrawn, mostly because the research proposed fell outside the NIGMS mission. This is comparable to the proportion that was withdrawn over the past 3 years.
Withdrawn applications represent a lot of wasted time and effort on the part of affected PIs and are the source of considerable frustration. So what can you do to minimize the chance of this happening to your ESI MIRA application in the future?
Continue reading “How do I know if my work fits in the mission of NIGMS?”
We’ve issued a funding opportunity announcement (FOA) PAR-19-367
to maintain continued support of our Maximizing
Investigators’ Research Award (MIRA) program. Under this new FOA,
investigators with an active NIGMS R35 grant (both early-stage and established
investigator MIRA) can submit renewal MIRA applications, and investigators with
a single-PI R01-equivalent NIGMS award (DP1, DP2, R01, R37, SC1) can submit new
Continue reading “NIGMS Continues Its MIRA Program”
For the past few months, NIGMS has been reviewing its HIV/AIDS grant portfolio. As the HIV/AIDS field has matured and the necessary research directions have become clearer, the HIV/AIDS-related grants we’ve supported have, appropriately, become more narrowly focused. Because of this, and after close consultation with leadership at the National Institute of Allergy and Infectious Diseases (NIAID), we’ve concluded that it’s in the best interest of the research to transition NIGMS’ HIV/AIDS portfolio to NIAID to allow improved scientific coordination, prioritization, and efficiency of management.
Continue reading “NIGMS-Managed HIV/AIDS Research Transitioning to NIAID”